Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, Abu-Omar A, Ziegler L, Guckelmus C, Urschel R, Schneitler S, Becker SL, Gärtner BC, Sester U, Sester M. · 2021
Read Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. by Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, Abu-Omar A, Ziegler L, Guckelmus C, Urschel R, Schneitler S, Becker SL, Gärtner BC, Sester U, Sester M. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8440177.txt.
Description
Schmidt and co-authors gauge immune responses to a mixed COVID-19 vaccine schedule in Germany. The plan paired a first dose of the ChAdOx1 vector vaccine with an mRNA booster. Data on safety reactions and immune strength for this mix were missing.
In 96 healthy adults, the mixed schedule raised spike-specific antibodies and CD4 T cells. Levels beat those from two vector doses and matched or topped two mRNA doses. CD8 T cell levels were higher than in either matched schedule. Side effects after the mixed boost were mild, much like mRNA boosting. The first vector dose caused the stronger reactions in both groups that got it.
Catalog record
| CREATOR | Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, Abu-Omar A, Ziegler L, Guckelmus C, Urschel R, Schneitler S, Becker SL, Gärtner BC, Sester U, Sester M. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |